Methylprednisolone + Prednisone + Rituximab
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Wegener's Granulomatosis or Microscopic Polyangiitis
Conditions
Wegener's Granulomatosis or Microscopic Polyangiitis
Trial Timeline
Jul 6, 2015 → Jun 7, 2022
NCT ID
NCT02115997About Methylprednisolone + Prednisone + Rituximab
Methylprednisolone + Prednisone + Rituximab is a approved stage product being developed by Roche for Wegener's Granulomatosis or Microscopic Polyangiitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02115997. Target conditions include Wegener's Granulomatosis or Microscopic Polyangiitis.
What happened to similar drugs?
1 of 2 similar drugs in Wegener's Granulomatosis or Microscopic Polyangiitis were approved
Approved (1) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02115997 | Approved | Completed |
Competing Products
2 competing products in Wegener's Granulomatosis or Microscopic Polyangiitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rituximab | Roche | Approved | 35 |
| Abatacept + placebo | Bristol Myers Squibb | Phase 3 | 40 |